✦ LIBER ✦

590 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer

✍ Scribed by Voi, M.; Fu, S.; Nemunaitis, J.; Bauman, J.; Bessudo, A.; Hamid, O.; Witta, S.; Dy, G.; Lai, C.; Laliberte, R.

Book ID: 122569563
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 61 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(12)72387-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

364 The first-in-human, first-in-class s

364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer

✍ T. Shimizu; A.W. Tolcher; P. LoRusso; K. Papadopoulos; A. Patnaik; L. Smith; M. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 47 KB

O-110 Preliminary results of a phase II

O-110 Preliminary results of a phase II study of celecoxib and weekly docetaxel in elderly (> 70 yrs) or PS2 patients with advanced non-small cell lung cancer (NSCLC)

✍ Gadgeel, Shirish M.; Shehadeh, Nasfet; Kraut, Michael J.; Wozniak, Antoinette; B 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 189 KB

Biomarker Analyses and Final Overall Sur

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)

✍ Fukuoka, M.; Wu, Y.-L.; Thongprasert, S.; Sunpaweravong, P.; Leong, S.-S.; Sriur 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 241 KB